What is he best known for?
The fields of study he is best known for:
His scientific interests lie mostly in Cancer research, Apoptosis, Pharmacology, In vivo and Navitoclax.
His studies deal with areas such as Cell culture, Survivin, Immunology, Cell cycle and Regulation of gene expression as well as Cancer research.
His Apoptosis study contributes to a more complete understanding of Biochemistry.
His In vivo research includes themes of Platelet and Paclitaxel.
His work carried out in the field of Navitoclax brings together such families of science as Venetoclax, Survival analysis, Leukemia and Neutropenia.
Saul H. Rosenberg has included themes like Oral administration and Obatoclax in his BH3 Mimetic ABT-737 study.
His most cited work include:
- An inhibitor of Bcl-2 family proteins induces regression of solid tumours (2807 citations)
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (1694 citations)
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor (1348 citations)
What are the main themes of his work throughout his whole career to date?
Saul H. Rosenberg mainly investigates Stereochemistry, Enzyme inhibitor, Cancer research, Biochemistry and Pharmacology.
His Stereochemistry research is multidisciplinary, incorporating perspectives in Biological activity, Structure–activity relationship, Chemical synthesis and Enzyme.
His studies in Cancer research integrate themes in fields like Cancer cell, Cancer, Cell culture, Apoptosis and Immunology.
His works in Programmed cell death and Bcl-2 family are all subjects of inquiry into Apoptosis.
His Pharmacology research includes elements of Venetoclax and Navitoclax, In vivo.
In his work, DNA repair is strongly intertwined with PARP inhibitor, which is a subfield of In vivo.
He most often published in these fields:
- Stereochemistry (30.32%)
- Enzyme inhibitor (25.81%)
- Cancer research (23.23%)
What were the highlights of his more recent work (between 2009-2021)?
- Cancer research (23.23%)
- Pharmacology (20.65%)
- Cancer (11.61%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, Pharmacology, Cancer, Cancer cell and Navitoclax.
The various areas that Saul H. Rosenberg examines in his Cancer research study include Histone, Bromodomain, BRD4 and Leukemia, Immunology.
The study incorporates disciplines such as Venetoclax, Blood flow and In vivo in addition to Pharmacology.
His In vivo research incorporates themes from Biochemistry, Nicotinamide, Adenosine triphosphate, Enzyme and NAD+ kinase.
His Cancer cell study incorporates themes from Nicotinamide phosphoribosyltransferase, Carcinogenesis, Apoptosis, Programmed cell death and Enzyme activator.
His biological study spans a wide range of topics, including Molecular biology and Multiple dosing.
Between 2009 and 2021, his most popular works were:
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (1694 citations)
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity (526 citations)
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). (304 citations)
In his most recent research, the most cited papers focused on:
Saul H. Rosenberg focuses on Navitoclax, Pharmacology, In vivo, Cell culture and Cancer.
Stem cell, Cell growth, Carcinogenesis and Downregulation and upregulation is closely connected to Cancer cell in his research, which is encompassed under the umbrella topic of Navitoclax.
In general Pharmacology, his work in Pharmacodynamics is often linked to Lymphocytopenia linking many areas of study.
His work in In vivo covers topics such as Apoptosis which are related to areas like Multiple dosing.
His Cell culture study combines topics from a wide range of disciplines, such as Small molecule and Cell biology.
As part of one scientific family, Saul H. Rosenberg deals mainly with the area of Cancer, narrowing it down to issues related to the Venetoclax, and often MCL1, Toxicity and Platelet.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
